Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03324776 · ClinicalTrials.gov registry record · Phase 3
Initiating Mealtime Ultra-Rapid Acting Insulin (Afrezza) in Uncontrolled Type 2 Diabetes Patients
A Phase 3 study of Type2 Diabetes, sponsored by Model Clinical Research.
- Completed
- Registry status
- Phase 3
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT03324776 is a Phase 3 study of Type2 Diabetes that has completed, run by Model Clinical Research. The registered enrollment target is 20 participants, below the 47,822-participant average among 20 other Type2 Diabetes trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03324776, a Phase 3 study of Type2 Diabetes, has completed, sponsored by Model Clinical Research.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
To examine the effects of adding prandial Afrezza inhaled insulin to patients with type 2 diabetes who are not controlled after at least 6 months of other diabetes treatments including oral agents, basal insulin, or GLP-1 use.
Conditions Studied
Interventions
- DRUG Afrezza Inhalant Product
Study Locations (1)
Maryland
- MODEL Clinical Research - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2017-10-16 |
| Est. Completion | 2020-06-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03324776
The ClinicalTrials.gov registry entry for NCT03324776 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 47,822-participant average among 20 other Type2 Diabetes trials with a reported enrollment target (100% lower). The listed sponsor is Model Clinical Research, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Type2 Diabetes appearing as the primary indexed condition, and to 1 intervention - of which Afrezza Inhalant Product is the first listed.
NCT03324776 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT03324776 about?
NCT03324776 is a clinical study titled "Initiating Mealtime Ultra-Rapid Acting Insulin (Afrezza) in Uncontrolled Type 2 Diabetes Patients". To examine the effects of adding prandial Afrezza inhaled insulin to patients with type 2 diabetes who are not controlled after at least 6 months of other diabetes treatments including oral agents, basal insulin, or GLP-1 use.
What is the current status of trial NCT03324776?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 20 participants. The study started on 2017-10-16. Estimated completion is 2020-06-10.
What conditions does trial NCT03324776 study?
This clinical trial studies the following conditions: Type2 Diabetes.
What interventions are being tested in trial NCT03324776?
The interventions under investigation include: Afrezza Inhalant Product (DRUG).
Who is sponsoring clinical trial NCT03324776?
This trial is sponsored by Model Clinical Research, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03324776 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type2 Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
iGlucose® Remote Patient Monitoring Device as an Adjunct to Routine Glucose Meter Devices for Glycemic Management and Control in Gestational Diabetes
RECRUITING · NA
-
SGLT2 Inhibitors, Ketones, and Cardiovascular Benefit Research Plan
RECRUITING · Early Phase 1
-
A Causative Role for Amylin in Diabetic Peripheral Neuropathy
RECRUITING
-
Brain Health in Youth With Normal Weight, Overweight and Obesity at Risk for Type 2 Diabetes (T2D)
RECRUITING
-
Effects of Sitagliptin in Individuals With Genetically Decreased DPP4
ACTIVE NOT RECRUITING · Phase 4
-
Reducing Metabolic Dysregulation in Obese Latina Breast Cancer Survivors Using Physical Activity
ACTIVE NOT RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.